Journal article

The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia

Lauren M Brown, Andrew Lonsdale, Andrea Zhu, Nadia M Davidson, Breon Schmidt, Anthony Hawkins, Elise Wallach, Michelle Martin, Francoise M Mechinaud, Seong Lin Khaw, Ray C Bartolo, Louise EA Ludlow, Jackie Challis, Ian Brooks, Vida Petrovic, Nicola C Venn, Rosemary Sutton, Ian J Majewski, Alicia Oshlack, Paul G Ekert

Blood Advances | AMER SOC HEMATOLOGY | Published : 2020

Abstract

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, and implementation of risk-adapted therapy has been instrumental in the dramatic improvements in clinical outcomes. A key to risk-adapted therapies includes the identification of genomic features of individual tumors, including chromosome number (for hyper- and hypodiploidy) and gene fusions, notably ETV6-RUNX1, TCF3-PBX1, and BCR-ABL1 in B-cell ALL (B-ALL). RNA-sequencing (RNA-seq) of large ALL cohorts has expanded the number of recurrent gene fusions recognized as drivers in ALL, and identification of these new entities will contribute to refining ALL risk stratification. We used RNA-seq on 126 ALL patients from ou..

View full abstract

Grants

Awarded by Cancer Australia PdCCRs


Awarded by Children's Cancer Foundation


Awarded by National Health and Medical Research Council


Awarded by SCOR grant from the Lymphoma and Leukemia Society


Funding Acknowledgements

The RQ-PCR testing was supported by Cancer Australia PdCCRs APP1128727 Sutton. The establishment and running of the Children's Cancer Centre Tissue Bank are made possible through the generous support of Cancer In Kids@RCH(www.cika.org.au), Leukaemia Auxiliary at RCH (LARCH), the Murdoch Children's Research Institute, and The Royal Children's Hospital Foundation. This work was supported by the Victorian Government's Operational Infrastructure Support Program; the Children's Cancer Foundation (Project 131 and 132); National Health and Medical Research Council grant 1140626; SCOR grant 7015-18 from the Lymphoma and Leukemia Society; and an Australian Government Research Training Program Scholarship (L.M.B.); and the Victorian Government's Operational Infrastructure Support Program. S.L.K. is supported by a fellowship from the Victorian Cancer Agency and I.J.M. is supported by a fellowship from the Victorian Cancer Agency and by the Felton Bequest.